Exela Pharma Company Profile
✉ Email this page to a colleague
What is the competitive landscape for EXELA PHARMA
EXELA PHARMA has twenty-three approved drugs.
There are seventeen US patents protecting EXELA PHARMA drugs.
Drugs and US Patents for Exela Pharma
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Exela Pharma | ELCYS | cysteine hydrochloride | SOLUTION;INTRAVENOUS | 210660-001 | Apr 16, 2019 | RX | Yes | Yes | 11,684,636 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Exela Pharma | ELCYS | cysteine hydrochloride | SOLUTION;INTRAVENOUS | 210660-001 | Apr 16, 2019 | RX | Yes | Yes | 10,912,795 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Exela Pharma | TRANEXAMIC ACID | tranexamic acid | SOLUTION;INTRAVENOUS | 212020-001 | Apr 15, 2019 | AP | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ||||
| Exela Pharma | AKOVAZ | ephedrine sulfate | SOLUTION;INTRAVENOUS | 208289-002 | Aug 2, 2021 | AP3 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ||||
| Exela Pharma | ELCYS | cysteine hydrochloride | SOLUTION;INTRAVENOUS | 210660-001 | Apr 16, 2019 | RX | Yes | Yes | 11,642,370 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Exela Pharma | DILTIAZEM HYDROCHLORIDE IN DEXTROSE 5% | diltiazem hydrochloride | SOLUTION;INTRAVENOUS | 215252-001 | Oct 28, 2021 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.

